Doctors Welcome Hepatitis C Drug Rivals, Gilead Sciences, Inc. (GILD) Still Leads
4/11/2014 6:19:01 AM
(Reuters) - Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.
Gilead, under fire from insurers and legislators for the $1,000-a-pill price of its Sovaldi drug, presented pivotal data on Friday at the European Association for the Study of the Liver conference in London, showing a cure rate of 94 percent after eight weeks of treatment with its experimental two-drug pill.
Help employers find you! Check out all the jobs and post your resume.
comments powered by